NSAIDs

Start with Aspirin. As you can see in the Aspirin structure above, the phenolic –OH is acetylated (OCOCH₃). Aspirin works by irreversibly acetylating the COX enzyme — the acetyl group is transferred to a serine residue in the active site. The remaining salicylate anion is the actual active moiety.

The carboxylic acid (–COOH) matters. Look at Salicylamide above — the only change is –COOH → –CONH₂ (amide). Notice what happens: analgesic activity is kept BUT anti-inflammatory activity is completely lost. Lesson: the acidic –COOH is essential for anti-inflammatory action, but not for analgesia.

Position of the phenolic –OH is critical. Placing the –OH group at the meta or para position (instead of ortho, as in all these structures) completely abolishes activity. Benzoic acid itself (no –OH at all) has only weak anti-inflammatory activity. The ortho relationship between –COOH and –OH is non-negotiable.

Substitution at the 5-position boosts potency. Compare Diflunisal with Aspirin — see that large 2,4-difluorophenyl group attached at the 5-position of the ring? This hydrophobic group dramatically increases anti-inflammatory activity and extends the duration of action. Halogen substitution on the aromatic ring generally increases both potency and toxicity.

Salt forms improve tolerability. As you can see in the Sodium Salicylate and Choline Salicylate cards, salicylic acid can be formulated as various salts. These are less irritating to the stomach than the free acid, though the active species is always the salicylate anion.

The 1-carbon spacer rule. Look at the Indomethacin structure above — the acidic –COOH is separated from the flat indole ring by exactly one carbon (–CH₂–). This distance is crucial because it mimics the double bonds at positions 5 and 8 of arachidonic acid, the natural substrate. If you increase this to 2 or 3 carbons, activity drops significantly.

Acidity is everything. The –COOH group cannot be replaced by other acidic groups (enolic, hydroxamic acid, sulfonamide, tetrazole) without losing activity. Converting it to an amide (–CONH₂) makes the drug completely inactive. Higher acidity = higher anti-inflammatory activity.

The N-benzoyl substitution pattern. In the Indomethacin structure, find the benzoyl group attached to the indole nitrogen. The para position of this benzoyl ring has a chlorine atom. Para-substitution with F, Cl, CF₃, or SCH₃ gives the most active compounds.

The indole nitrogen is dispensable. Compare Indomethacin with Sulindac side by side. In sulindac, the indole NH has been replaced by a carbon (making it an indene). Yet sulindac is still active! This SAR tells us: the aromatic flat surface matters, not the specific heteroatom.

Prodrugs mask the acid. Look at Nabumetone — there's no carboxylic acid at all in its structure. It's a non-acidic prodrug that gets metabolized in the liver to the active acetic acid form. This is a strategy to reduce GI irritation before the drug reaches its target.

The α-methyl group: acetic → propionic. Look at the Ibuprofen structure. Compare it mentally to the acetic acids (like indomethacin). The key difference? There's a methyl group (–CH₃) on the α-carbon (the carbon directly attached to –COOH). This one substitution enhances anti-inflammatory action while reducing side effects.

Stereochemistry: S = active, R = inactive. That α-carbon with the methyl group is chiral. Only the S-enantiomer fits the COX active site. But the body has an enzyme that converts the inactive R-enantiomer into the active S-enantiomer (in vivo epimerization). This is why most of these drugs are sold as racemic mixtures.

Same 1-carbon spacer rule applies. As you can see in both Ibuprofen and Naproxen, the –COOH is still one carbon away from the flat aromatic system. The same SAR rule from acetic acids carries over.

The –NH– bridge is unique and essential. Look at any of the three fenamate structures above. Unlike acetic/propionic acids, fenamates connect their two aromatic rings through a secondary amine (–NH–). This nitrogen is absolutely required — replacing it with O, CH₂, or anything else kills activity. This unique NH linker is also why fenamates have lower GI irritation.

Substitution on the N-aryl ring: 3' position is best. For monosubstitution, the activity order is: 3' > 2' >> 4'. Look at Flufenamic Acid — the CF₃ is at the 3' position, making it particularly potent. The 4' (para) position gives very weak activity.

Non-coplanarity boosts binding. Compare Mefenamic Acid (one ortho-CH₃) with Meclofenamic Acid (two ortho-Cl at 2' AND 6'). The two bulky ortho substituents in meclofenamic acid force the N-aryl ring to twist out of plane. This non-coplanar conformation actually enhances binding — so meclofenamic > mefenamic in activity.

COOH must be ortho. In all fenamates above, the –COOH is at the ortho position relative to the NH bridge. Moving it to meta or para makes the drug inactive. Also, substituting anything on the anthranilic acid ring itself reduces activity.

Acidity without a carboxylic acid. Look at the structure of Piroxicam — there is no –COOH group, yet this drug is acidic. The acidity comes from the enolic 4-hydroxyl group on the 1,2-benzothiazine ring. This was the first class of NSAIDs to show you don't need a free carboxylic acid.

R₁ must be methyl. On the benzothiazine nitrogen, the optimal substituent is methyl (–CH₃). Both Piroxicam and Meloxicam have this.

The carboxamide R group: heteroaryl wins. The amide side chain (CONHR) determines potency. Aryl or heteroaryl R groups are far better than simple alkyl chains. The two best are 2-pyridyl (piroxicam) and 2-thiazolyl (meloxicam).

Long half-life = good and bad. Oxicams have longer plasma half-lives due to slower elimination → better dosing schedules. However, longer exposure also means higher incidence of GI side effects.

The selectivity trick: a side pocket. COX-2 has a larger active site than COX-1 — it has a "side pocket" (Val523 instead of Ile523). Coxibs exploit this. Look at Celecoxib — the bulky sulfonamide (–SO₂NH₂) fits into this extra pocket of COX-2 but can't fit into COX-1's narrower channel.

The key pharmacophore: –SO₂NH₂ or –SO₂CH₃. Both Celecoxib (sulfonamide) and Rofecoxib (methylsulfone) contain a sulfone/sulfonamide group that occupies the COX-2 side pocket. Without this group, selectivity is lost.

The COX-2 selectivity trade-off. By sparing COX-1, coxibs cause fewer GI side effects. BUT COX-2 also produces prostacyclin (PGI₂), a vasodilator and anti-platelet agent. Blocking COX-2 tips the balance toward thromboxane → increased cardiovascular risk. This is why Rofecoxib was withdrawn in 2005.

Emerging uses beyond inflammation. COX-2 is induced in the inflammatory plaques of Alzheimer's disease and in various carcinomas. This has opened research into coxibs for treating Alzheimer's and preventing certain cancers.

Analgesic + antipyretic, but NO anti-inflammatory. Look at the Acetaminophen structure. Notice something missing? There's no carboxylic acid group — and therefore no anti-inflammatory activity. Acetaminophen works centrally (in the CNS) by inhibiting COX in the brain, not peripheral COX at inflammation sites.

No GI side effects. Because acetaminophen doesn't inhibit peripheral COX-1 (which protects the stomach lining), it causes no gastric ulceration or bleeding — unlike essentially every other NSAID. This makes it the safest option for long-term use.

The prodrug story. Acetaminophen is the active metabolite of both Acetanilide and Phenacetin. Acetanilide (just –NHCOCH₃) gets hydroxylated. Phenacetin (–OC₂H₅ instead of –OH) gets dealkylated. Both approaches work, but the parent compounds have toxicity issues.

Key pharmacophore: para-aminophenol. The essential core is a benzene ring with an –OH and –NHCOCH₃ in the para (1,4) relationship. The N-acetyl group is essential — replacing it reduces potency. The –OH must be free (not blocked) for the active form.